Tune Therapeutics

About Tune Therapeutics

Tune Therapeutics is a company focused on transforming human healthspan through mastering the epigenome. Founded on cutting-edge advances in gene regulation, their mission is to redefine genetic medicine by using 'genetic tuning' technology to control gene activity, addressing cellular dysfunction and disease. They aim to expand the scope of genetic medicine to target common, chronic, and age-related diseases, pursuing lifelong health with innovative therapies.

Products & Services

TEMPO Platform:A proprietary genetic tuning platform that allows precise control over gene expression without altering DNA sequences, enabling applications in genetic medicine for a wide range of diseases.

Tune-401:A first-in-class epigenetic silencer for Hepatitis B, moving into clinical trials as a novel therapeutic approach.

Specialties

Epigenetic Editing Gene Regulation Genetic Tuning Chronic Disease Treatment Age-Related Disease Therapy

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 175000000 MR: - FA: over $175M FAN: 175000000	D: 2025-01-12 FD: 2025-01-12	4 investors

Series B Latest

2025-01-12

$175.0M

4 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Alicia Collins

VP, External Manufacturing and Supply Chain

A

Aiden Jones

Associate Scientist

C

Cameron Lee

Principal Scientist

E

Edith Nalbandian

Principal Scientist

H

Heidi Zhang

Chief Development Officer

D

Derek Jantz

Chief Scientific Officer

View 62 more team members with Pro

Unlock Full Team Directory

Recent News